Press Releases

Below, you will find a list of all our latest press releases. Clicking any of the titles below will open up the full text of the press release in Adobe PDF format or a link to the News Article.

12/2/2016
Courtagen Life Sciences Partners with Certainty Health to Pioneer the First Collaborative Ecosystem for Neurological Disorders
The innovative partnership will support value-based care, connecting physicians, and improving patient care delivery while reducing health care costs.
12/1/2016
Medicinal Genomics and Courtagen Life Sciences Announce CannMed 2017, the Personalized Cannabinoid Medicine Conference, April 9-­11, 2017
The 2nd annual CannMed 2017 Conference will convene leaders in research, medicine, and therapeutics to discuss cannabis-based therapies for cancer, and neurological and inflammatory disorders, and developments in cannabis genetics and safety.
11/11/2016
Courtagen Offers Wide Array of Genetic Testing Options for Epilepsy - November is Epilepsy Awareness Month
Knowing the genetic basis of a patient’s epilepsy is valuable for obtaining a definitive diagnosis, estimating prognosis, determining recurrence risks, and guiding treatment choices. Courtagen offers a broad range of genetic testing panels for epilepsy, including recently-added epiSEEK® Spotlight Panels, designed to target genes that have been reported in association with specific phenotypes for epilepsy and seizure disorders.
9/15/2016
Courtagen Life Sciences Collaborates with Astellas Pharma For Mitochondrial Disorder Drug Development
Courtagen enters data partnership with Astellas for early stage therapeutic development program to address mitochondrial disease.
8/25/2016
U.S. Patent Granted for Courtagen’s Novel DREAM™ PCR Decontamination Technology
Novel DREAM PCR Eliminates the Need for Isolated Pre- and Post-PCR Contamination Control Areas in Next-Generation Sequencing and Genomics Pipelines
5/3/2016
Courtagen Life Sciences Adds Pediatric Neurologist, Ngoc Minh Le, M.D., to the Company’s Clinical Team
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the addition of Ngoc Minh Le, M.D. to the company’s clinical team as Medical Consultant.
4/20/2016
Medicinal Genomics Revolutionizes Cannabis Industry with Introduction of Strain ID & Certification Service
Medicinal Genomics Corporation (MGC), a company that applies state-of-the-art life science technology to cannabis and hemp plant genetics, today announced StrainSEEK™, a revolutionary genetics based service designed to identify and certify cannabis and hemp strains, providing growers with the identity, heritage, and chemistry of the cannabis and hemp plants they are cultivating. Consumers and clinicians are, for the first time, able to identify the exact strain and key characteristics of the cannabis and hemp they are purchasing, enabling confidence in the quality and reliability of the product.
4/6/2016
CannMed 2016 Conference to be Live Streamed Including the Keynote Speech by Noted Israeli Marijuana Research Pioneer Dr. Raphael Mechoulam
Medicinal Genomics and Courtagen Life Sciences today announced that the entire full day program of CannMed 2016 will be live streamed on Monday, April 11th, 2016. CannMed 2016, a Personalized Cannabinoid Medicine Conference, will be held at The Joseph B. Martin Conference Center at The Harvard School of Medicine April 10-11, 2016. Registration for the live streaming is now available for $99 on the CannMed website.
3/15/2016
Dr. Raphael Mechoulam to Receive Lifetime Achievement Award at CannMed 2016 Conference in Cambridge, MA in April
Pioneering Israeli Scientist Known as “The Father of Marijuana Research,” Dr. Raphael Mechoulam, to be Honored for Decades of Discoveries
3/8/2016
Courtagen and Medicinal Genomics Announce Expanded Speaker List for CannMed 2016 - 1st Annual Cannabis Medical Research Conference Being Held in Cambridge, MA in April
Leaders in Cannabinopathic Medicine and the Medicinal Cannabis Industry Join Presenters Including Dr. Raphael Mechoulam, Pioneering Israeli Scientist Known as “The Father of Marijuana Research”
2/11/2016
CannMed2016 Announces That Kyle Turley, Former NFL Pro Bowler and Leading Cannabis Advocate, Will Speak at 1st Annual Cannabis Medical Research Conference Being Held in Cambridge, MA in April
Medicinal Genomics and Courtagen Life Sciences, today announced that former All-Pro NFL offensive lineman, Kyle Turley, will be a featured speaker at CannMed2016. This first annual Personalized Cannabinoid Medicine Conference will be held at The Joseph B. Martin Conference Center at The Harvard School of Medicine April 10-11, 2016. The conference will feature internationally recognized thought leaders, scientists, physicians, and advocates working to advance research into the endocannabinoid system and cannabinoid therapeutics.
1/21/2016
Courtagen Life Sciences Receives New York State Clinical Laboratory Approval
Courtagen Life Sciences expands availability of clinical genetic testing for pediatric neurology and metabolic disorders to New York state.
1/13/2016
Medicinal Genomics Corporation and Courtagen Life Sciences Announce CannMed 2016, the Personalized Cannabinoid Medicine Conference, April 10-11, 2016
CannMed 2016 Personalized Cannabinoid Medicine Conference will convene leaders in research, medicine, and therapeutics to discuss real-world issues around cannabis-based therapies for neurological disorders
7/15/2015
Courtagen Closes Expanded Financing Totaling ~$20 Million; Bunker Hill, First Analysis, and Others Join as Investors
Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company, announced today that the company has closed its recent financing endeavor, with ~$20 million of new growth equity. Courtagen sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders.
5/20/2015
Courtagen Life Sciences Appoints Thomas Fairfield to the Company’s Board of Directors
Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Thomas Fairfield to the company’s Board of Directors.
5/12/2015
Courtagen Life Sciences Appoints Dr. Joe Keegan to the Company’s Board of Directors
Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Dr. Joe Keegan to the company’s Board of Directors.
5/5/2015
Courtagen Life Sciences Appoints Reymundo Lozano, MD to the Company’s Clinical And Strategic Advisory Board
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the appointment of Reymundo Lozano, MD to the company’s Clinical and Strategic Advisory Board.
4/29/2015
Courtagen Life Sciences Announced Today the Launch of rxSEEK™ Epilepsy Drug Metabolism Test for Epilepsy and Seizure Disorders
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of a Next Generation Sequencing test focused on detection of anti-epileptic drug (AED) compatibilities and interactions for patients receiving treatment for epilepsy or other seizure disorders.
4/27/2015
Courtagen Life Sciences Appoints Helio Pedro, MD to the Company’s Clinical And Strategic Advisory Board
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the appointment of Dr. Helio Pedro to the company’s Clinical and Strategic Advisory Board.
4/23/2015
Courtagen Initiates Partnership with Pronto Diagnostics and Medica Labs for Distribution of Clinical Next Generation Sequencing Tests for Neurological and Metabolic Disorders
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today international distribution agreements with Pronto Diagnostics Ltd., headquartered in Tel Aviv, Israel, and Medica Labs, headquartered in Bangkok, Thailand. Courtagen continues to expand its international presence, and is pursuing similar commercial relationships with leading distributors in markets around the world.
4/14/2015
Courtagen Life Sciences Announced Today the Launch of New Tests for Epilepsy and Mitochondrial Disorders
Courtagen added the nucSEEK Focus Nuclear Mitochondrial Gene Panel and epiSEEK Focus Epilepsy and Seizure Disorder Panel to the company’s test offerings. The new tests will complement the current nucSEEK Comprehensive Nuclear Mitochondrial Exome Panel and epiSEEK Comprehensive Epilepsy and Seizure Disorder Panel, respectively. Physicians will now have more flexibility to choose the most appropriate test for their patient.
3/24/2015
Courtagen Announces Today the Release of a New Genetic Test, lysoSEEK™
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of a new genetic test, lysoSEEK™, which is focused on early identification of genes associated with potentially treatable lysosomal storage disorders.
7/16/2014
Five Innovative Organizations Announce Collaboration to Study Biological Causes and Contributors to Autism
CNNH, along with partners Bancroft, Courtagen Life Sciences, Coriell Institute for Medical Research & the Mitochondrial Disease Laboratory of St. Christopher's Hospital for Children, announces the award of a new grant to study genetic abnormalities and their clinical manifestations in Autism
6/27/2014
Courtagen Presenting new data at the 2014 Cyclic Vomiting Association Conference in Milwaukee, WI
Courtagen Life Sciences, Inc. announces the presentation of data and case studies at the Cyclic Vomiting Association Conference being held in Milwaukee, WI from June 27-29, 2014.
6/26/2014
Bioinn Molecular Diagnosis to Provide Courtagen’s Clinical Testing to Clinicians in Taiwan
Courtagen Initiates Partnership with Bioinn Molecular Diagnosis for Distribution in Taiwan of Clinical Next Generation Sequencing Tests for Neurological and Metabolic Disorders
6/19/2014
Courtagen Announces Partnership with Seizure Tracker to Better Understand Relationships Between Genetics, Seizure Activity and Anti-epileptic Treatments
Courtagen Life Sciences Announces Partnership with Seizure Tracker to Better Understand Relationships Between Genetics, Seizure Activity and Anti-epileptic Treatments The arrangement with Seizure Tracker will enhance Courtagen’s ZiPhyr® Molecular Information Platform to improve understanding of seizure treatment and patient outcomes.
5/29/2014
Courtagen Initiates Partnership with Sciencewerke for International Distribution of Clinical Next Generation Sequencing Tests for Neurological and Metabolic Disorders
Sciencewerke to Provide Courtagen’s Clinical Testing to Clinicians in Singapore, Malaysia, and Indonesia.
5/5/2014
Courtagen launched devSEEK™ and devACT™ Clinical Genetic Tests For Neurodevelopmental Disorders, Developmental Delay, Intellectual Disability, and Autism Spectrum Disorders
Courtagen Life Sciences Announced Today the Launch of Two New Next Generation DNA Sequencing Tests for Neurodevelopmental Disorders, Developmental Delay, Intellectual Disability, and Autism Spectrum Disorders
4/22/2014
Courtagen Life Sciences Announces Collaboration with Connecticut Children’s Medical Center (CCMC) for Genetic Analysis of Autism Spectrum Disorder (ASD) Patients
Courtagen Life Sciences, Inc., an innovative molecular information company, announced today a collaboration with Connecticut Children’s Medical Center to utilize Courtagen’s sophisticated Next Generation Sequencing assays to help identify and characterize alterations found in genes associated with ASD.
4/9/2014
Courtagen Life Sciences Integrates SimulConsult’s Genome-Phenome Analyzer to Enhance the Clinical Genetic Analysis for Neurological and Metabolic Disorders
Courtagen signed a licensing agreement with SimulConsult to incorporate their innovative diagnostic software into Courtagen’s ZiPhyr® Molecular Information Platform.
4/2/2014
Courtagen to Provide Genetic Profiling of Children with Intractable Epilepsy to Support Clinical Developments with Cannabidiol
Using the latest next-generation sequencing technologies, Courtagen is collaborating with various academic centers and US physicians to profile the genomes of intractable epilepsy patients to stratify response to cannabidiol (CBD).
3/24/2014
Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals for Leigh Syndrome and Other Mitochondrial Disorders
WOBURN, MA, March 25, 2014 – Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
3/6/2014
Courtagen Announces the Presentation of a Novel Cause of Polygenic Mitochondrial Disease at the 2014 Society for Inherited Metabolic Disease (SIMD Meeting)
Richard Boles, M.D., will be presenting data from Courtagen's nucSEEK® Comprehensive Sequence Analysis of the Nuclear Mitochondrial Genome. DNA samples from 581patients, referred by clinicians to Courtagen to test for suspected mitochondrial disease, were analyzed using Courtagen’s nucSEEK® Comprehensive Sequence Analysis test. This test sequences over 1,100 nuclear-­‐encoded genes affecting normal mitochondrial function. From this analysis, putative mutations were found to be highly associated with chronic, common functional symptomatology including pain, fatigue, dysmotility, and dizziness.
2/25/2014
Courtagen Expands Next Generation Sequencing Test Menu for Epilepsy and Seizure Disorders
New Infancy and Childhood Epilepsy Panel and Updated epiSEEK®, the Most Comprehensive Sequencing Panel for Seizure Disorders. Courtagen Life Sciences, Inc. announces the immediate availability of an expanded Next Generation Sequencing test menu for epilepsy and seizure disorders. The latest epiSEEK® comprehensive panel features exceptional coverage of 489 genes associated with seizure disorders. In addition, Courtagen now offers a new Infancy and Childhood Epilepsy Panel, targeting 70 genes, for physicians requesting a more focused approach.